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ABSTRACT 
 
ACTIVATED SIGNALING PATHWAYS AND APOPTOTIC 
MECHANISMS IN RESVERATROL APPLIED CHRONIC MYELOID 
LEUKEMIA CELLS AND THE INVOLVEMENT OF CERAMIDE 
METABOLIZING GENES ON THESE MECHANISMS 
 
Resveratrol, an important phytoalexin in many plants, has cytotoxic effects on 
several cancer cells. Ceramide is a significant sphingolipid which affects many 
signaling pathways regulating cell senescence, migration, and cell cycle arrest. 
Intracellular ceramide level is balanced by glucosylceramide synthase (GCS), the 
converter of ceramide to glucosylceramide, and sphingosine kinase-1 (SK-1) that 
convert ceramide to sphingosine 1-phosphate (S1P). Ceramide functions as an apoptotic 
molecule whereas glucosylceramide S1P function as anti-apoptotic. An important cell-
permeable analogue of natural ceramides, C8:ceramide, increases intracellular ceramide 
levels significantly, while 1-phenyl-2-decanoylamino-3-morpholino-1-propanol 
(PDMP) and SK-1 inhibitor increase accumulation of ceramides by inhibiting GCS and 
SK-1, respectively. Chronic myelogenous leukemia (CML), a hematological disorder, 
results from the generation of BCR/ABL oncogene. 
In this study, we examined the roles of ceramide metabolizing genes in 
resveratrol-induced apoptosis, and the expression profiles of 84 genes underlying 
apoptosis, cell cycle control, DNA damage repair, and invasion and metastasis in human 
K562 CML cells treated with resveratrol. There were synergistic cytotoxic and 
apoptotic effects of resveratrol with coadministration of C8:ceramide, PDMP and SK-1 
inhibitor. We observed significant increases in expression levels of LASS genes, and 
decreases in expression levels of GCS and SK-1 in K562 cells in response to increasing 
concentrations of resveratrol. There were also significant increases in the expression 
levels of SERPINB5, FAS, TNFRSF, MTSS that are related with tumor suppression, 
and decreases in Myc expression. 
Our data, in total, showed for the first time that resveratrol might kill CML cells 
through increasing intracellular generation and accumulation of apoptotic ceramides. 
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ÖZET 
 
RESVERATROL UYGULANAN KRONİK MİYELOİD LÖSEMİ 
HÜCRELERİNDE TETİKLENEN SİNYAL İLETİ YOLAKLARI, 
ETKİNLEŞTİRİLEN HÜCRE ÖLÜM MEKANİZMALARI VE BU 
MEKANİZMALAR ÜZERİNE SERAMİD METABOLİZMASI 
GENLERİNİN ETKİLERİ 
 
 Bitki kaynaklı bir antioksidan olan resveratrolün çeşitli kanser hücreleri üzerinde 
sitotoksik etkilerinin olduğu bilinmektedir. Önemli bir biyoaktif sfingolipid olan 
seramid, hücre çoğalması, yaşlanması ve apoptoz gibi önemli hücre içi sinyal ileti 
yolaklarını kontrol etmektedir. Seramidler hücre içinde LASS genleri tarafından 
sentezlenmektedir. Apoptotik bir molekül olan seramid, glukozilseramid sentaz (GSS) 
enziminin katalizörlüğünde antiapoptotik glukozilseramide, sfingozin kinaz-1 (SK-1) 
enziminin katalizörlüğünde ise antiapoptotik sfingozin 1-fosfata dönüşmektedir. Önemli 
bir seramid analoğu olan C8:seramid, hücre membranından geçebilme özelliğine 
sahiptir ve hücre içi seramid oluşumunu önemli ölçüde arttırmaktadır. Glukozilseramid 
sentaz inhibitörü 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) ve SK-
1 inhibitörü ise seramidin hücre içinde birikmesine neden olmaktadır. Kronik miyeloid 
lösemi, resiprokal translokasyon sonucunda oluşan BCR/ABL onkogeni nedeniyle 
ortaya çıkan bir hematolojik kanser türüdür. 
 Çalışmamızda, resveratrol uygulanan K562 hücrelerinde seramid metabolize 
eden genlerin ve hücre yaşlanması, apoptoz, hücre döngüsü kontrolü ve metastaz gibi 
çeşitli hücresel olayı kontrol eden 84 farklı genin ekspresyon düzeyleri belirlenmiştir. 
Çalışma sonucunda, resveratrol ile birlikte uygulanan C8:seramid, PDMP veya SK-1 
inhibitörünün K562 hücreleri üzerinde sinerjistik sitotoksik ve apoptotik etkilerinin 
olduğu ortaya konmuştur. Ayrıca, artan dozlarda resveratrol uygulanan K562 
hücrelerinde LASS genlerinin ekspresyon düzeyleri doza bağlı olarak artış gösterirken 
SK-1 ve GSS genlerinin ekspresyon düzeyleri doza bağlı azalma göstermiştir. Öte 
yandan, tümör baskılanmasında görevli SERPINB5, FAS, TNFRSF, MTSS gibi 
genlerin ekspresyon düzeylerinde önemli artışlar gözlenirken Myc onkogeninin 
ekspresyonunda azalma gözlenmiştir. 
 Sonuç olarak, bu çalışmada elde edilen bulgular, K562 hücrelerinde görülen 
resveratrol-aracılı apoptozda seramid metabolize eden genlerin de rollerinin 
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olabileceğini ve ayrıca SERPINB5 gibi önemli tümör baskılayıcı genlerin 
ekspresyonunun da bu apoptotik yolakta rol aldığını ilk kez ortaya koymuştur. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1. Chronic Myeloid Leukemia (CML) 
 
Chronic myeloid leukemia is a hematological disorder arisen from the reciprocal 
translocation between BCR (Breakpoint cluster region) gene on chromosome 22, and 
ABL (Abelson murine leukemia virus) gene on chromosome 9, t(9;22)(q34;q11), 
resulting in the formation of Philadelphia (Ph) chromosome. This Ph chromosome 
encodes BCR/ABL fusion protein, which has constitutively active tyrosin kinase 
activity. BCR/ABL consists of more than one different domains. At the N-terminal 
domain of this protein, there is a cap structure that has two isoforms because of 
alternative splicing. One another domain, tyrosine kinase domain is split into two 
subdomains called as Src-homolgy domains, consisting of SH2 and SH3 (Quinta´s-
Cardama and Cortes 2009). 
Depending on the alternative splicing patterns, molecular weights of BCR/ABL 
fusion transcripts could be 190-, 210-, or 230 kDa. While 210 kDa-oncoprotein is 
mainly found in  CML and 5 -10% of adults with acute leukemia, 185 kDa-oncoprotein 
exists  in acute lymphocytic leukemia, and also 230 kDa oncoprotein is mainly found in 
chronic neutrophilic leukemia. In normal conditions, 145-kDa-ABL protein, which 
localizes in the nucleus, operates in several cellular signaling events such as cell cycle 
regulation, cellular response to toxic agents, and advising about the environmental 
conditions (Quinta´s-Cardama and Cortes 2009). 
After the fusion of ABL with BCR, ABL no longer translocates into the nucleus, 
therefore it retains in the cytoplasm. However, it gains limitless tyrosine kinase activity 
because it is no longer regulated. The resultant BCR/ABL oncoprotein affects many 
downstream signaling pathways resulting in uncontrolled cell proliferation, growth 
factor autonomy, and evasion of apoptosis, which are some of the six hallmarks of 
cancer. BCR/ABL induces several signal transduction pathways which mediate cellular 
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proliferation and cause the disruption of the genetic maintenance. Such pathways are 
MAPK, PI3K, and RAS (Jagani, et al. 2008). 
CML is characterized by three stages: chronic, accelerated and blast crisis. 
While chronic phase lasts few years, accelerated phase lasts 4-6 months, and blast crisis 
phase lasts a few months (Perrotti, et al. 2005). 
 
 
 
 
Figure 1.1. Generation of CML phenotype  
(Adapted from: Frazer, et al. 2007)  
 
 
Statistically, the incidence of CML is 1-2 per 100,000 population per year. The 
median age of presentation is 45 to 55 years, accounting for 20% of leukaemia affecting 
adults. As in all leukemias, males are affected more than females in CML, with a ratio 
of 2:1 (Frazer, et al. 2007). 
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1.1.1. Downstream Signaling Pathways of BCR/ABL 
 
1.1.1.1. BCR/ABL and STAT 
 
The members of signal transduction and activators of transcription (STAT) 
family occupy in several signaling pathways such as cell growth, inflammation, 
differentiation, apoptosis, etc. STAT signaling begins with the binding of a ligand to 
cytokine or growth receptors followed by the phosphorylation, dimerization, and also 
translocation of STAT (Yu, et al. 2009).  
Due to having constitutive tyrosine kinase activity BCR/ABL phosphorylates 
and activates STAT-1 and -5 constitutively. Active STAT-5 triggers the expressions of 
anti-apoptotic genes such as Bcl-xL (Jagani, et al. 2008). 
 
1.1.1.2. BCR/ABL and NFκB  
 
NFκB functioning as dimers can be activated by several stimulants such as 
viruses, cytokines, and oxidative stress. NFκB activity is regulated by the protein IκB 
(inhibitor of κB), which retains NFκB in the cytoplasm. By the phosphorylation and 
ubiquitinylation, IκB is degraded, therefore the free and active NFκB can enter the 
nucleus, and mediates the expression of several genes related with cell survival 
processes (Li and Sethi 2010). 
In many cancer cells, NFκB is constantly activated, and this is generally 
considered with the development of resistance against apoptosis. Several studies have 
reported that CML cells with BCR/ABL expression overexpress the p65 (RelA), active 
subunit of NFκB (Li and Sethi 2010). In addition, for generation of tumors in nude mice 
by the transformation of hematopoetic cells with BCR/ABL, constant NFκB activation 
was found to be necessary (Jagani, et al. 2008). 
 
1.1.1.3. BCR/ABL and Ras Signaling 
 
In CML cells expressing BCR/ABL, Ras signaling is constitutively active. In 
murine bone marrow cells, while Ras is inactivated, it has been observed that the 
transformation potential of BCR/ ABL decreases (Downward 2003). 
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The adapter protein Grb2 is the dominant molecule that supplies the connection 
between BCR/ABL and Ras signaling pathway. This adapter protein binds to tyrosine 
residue 177 of BCR part of BCR/ABL by its SH2 domain. In vivo studies have been 
revealed that the pathways Ras and PI3-K/Akt are quite significant for carcinogenesis in 
CML (Jagani, et al. 2008). 
 
1.1.1.4. BCR/ABL and PP2A Phosphatase 
 
Studies have reported that in CML blast crisis, BCR/ABL causes an increase in 
the expression levels of SET gene, the inhibitor of PP2A, which is tumor suppressor 
serine/threonine protein phosphatase. Inhibition of PP2A phosphatase by SET leads to 
inactivation of pro-apoptotic molecules such as Bad. However, this inhibition of PP2A 
leads to overexpression of the genes such as Akt and Erk that are related with cell 
survival and growth (Jagani, et al. 2008). 
The studies on CML cell lines that are imatinib-resistant and –sensitive have 
revealed that reactivation of PP2A causes the inhibition of cell proliferation and 
survival molecules, the repression of BCR/ABL, and even the degradation of 
BCR/ABL. Therefore, PP2A should be inhibited in order to provide BCR–ABL-
mediated leukemogenesis (Perrotti and Neviani 2006). 
 
1.1.1.5. BCR/ABL and PI3-K/Akt Pathway 
 
Phosphoinositide-3 kinase (PI3-K), a type of lipid kinase, performs critical roles 
in many cellular processes such as survival, growth, mobility, and proliferation 
(Carnero 2010). Many studies have been indicated that BCR/ABL expression activates 
PI3-K (Steelman, et al. 2004, Naughton, et al. 2009). This active PI3-K converts PIP2 to 
PIP3 via phosphorylation. PIP3 in turn activates Akt. Akt then regulates the functions of 
many molecules such as Mdm-2, caspase-9, mTOR, Bad, and FoxO (Jagani, et al. 
2008). When phosphorylated by Akt, Bad retains in the cytoplasm and cannot promote 
its apoptotic effects. Despite that, in vitro studies have indicated that Bad sequestration 
is not fundamental for providing survial that is BCR/ABL-mediated (Neshat, et al. 
2000). In addition, one another study has indicated that CML cells treated with PI3-K 
inhibitor at chronic, acute, and blast crisis phases form less colonies than untreated 
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ones. Like that, CML cells treated with Akt inhibitor also showed decreased colony 
formation. These studies also were also confirmed by in vivo studies (Jagani, et al. 
2008). 
When BCR/ABL and inhibitor of Akt-expressing marrow cells were 
transplanted into SCID mice, leukemia growth was significantly decreased compared to 
control group (Skorski, et al. 1997). Moreover, PI3-K inhibitor and imatinib have been 
reported that they act synergistically on triggering apoptosis in CML cells at the phases 
chronic or blast crisis. Besides Akt inhibitor treatment have sensitized imatinib-resistant 
CML cells to apoptosis (Klejman, et al. 2002). Furthermore some other studies have 
reported that PI3-K/Akt signaling is required for CML cells in order to develop 
resistance against imatinib (Jagani, et al. 2008). 
 
1.1.2. Therapeutic Approaches for CML 
 
1.1.2.1. Allogeneic Stem Cell Transplantation 
 
In allogeneic stem cell transplantation, patient receives stem cells providing 
blood formation from a donor that is genetically similar. Since 1970, allogeneic stem 
cell transplantation has been used as an effective therapy for CML. Anyway, this 
approach could be resulted in deaths in many cases (Goldman and Melo 2003).  
Several reports before imatinib era have implicated that bone marrow 
transplantation provide many patients survival chance. However, emergence of graft 
versus host disease after transplantation is an important drawback of this therapy 
(Frazer, et al. 2007). 
 
1.1.2.2. Interpheron Alpha 
 
A biological glycoprotein, interpheron alpha (IFN-α) inhibits proliferation and 
viral infection. It has been used since 1980s, and many studies have revealed the effects 
on IFN- α on survival lengths of CML patients. 
When combined with other therapeutic agents, its cytotoxic efficacy has 
increased significantly, however, the disease has not been entirely ameliorated (Frazer, 
et al. 2007). 
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1.1.2.3. Imatinib Mesylate (STI571) 
 
Widespread existence of BCR/ABL oncoprotein in patients with CML made this 
protein an open target for therapeutic applications, therefore tyrosin kinase inhibitors 
have been developed for therapy. Normally, ATP binds to kinase domain of BCR/ABL, 
by this way, it phosphorylates tyrosine residues on the substrate. Imatinib mesylate (STI 
571, Gleevec, Novartis, Switzerland), the widely used therapeutic agent, blocks binding 
of ATP to the ATP-binding pocket of BCR/ABL, thus tyrosine kinase activity fails 
(Fausel 2007). Since 2001, imatinib has been used as “gold standard therapy” due to its 
strong cytotoxic effects on CML cells (Frazer, et al. 2007). 
Comparative studies have revealed that imatinib has more endurable and 
excellent effects than IFN- α. Presently, doctors are suggesting that patients recently 
diagnosed with CML should be treated with imatinib. Allogeneic stem cell 
transplantation should be referred only when imatinib therapy do not respond (Frazer, et 
al. 2007). 
 
1.1.2.4. Nilotinib (AMN107) 
 
As imatinib does, nilotinib, one of the second generation tyrosine kinase 
inhibitors, binds to ATP-binding pocket of BCR/ABL resulting in the inhibition of 
BCR/ABL oncoprotein function. Topographically, nilotinib is more appropriate to the 
BCR/ABL oncoprotein than imatinib therefore it binds firmlier resulting in more 
efficient and more susceptible drug action (Frazer, et al. 2007).  
Furthermore, many studies have indicated that CML patients with imatinib 
resistance are more susceptible to nilotinib. 
 
1.1.2.5. Dasatinib (BMS-354825) 
 
In contrast to imatinib and nilotinib, dasatinib functions through binding both 
active and inactive forms of BCR/ABL. It has a high affinity to BCR/ABL kinase 
domain since it is quite elastic in binding to several conformational structures of 
BCR/ABL (Shah, et al. 2004). Despite that, due to having a potential to bind the other 
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members of Src kinase family, dasatinib is not the most specific inhibitor of BCR/ABL 
kinase activity (Frazer, et al. 2007). 
In the course of time, however, cells could develop resistance against imatinib, 
and the other therapeutic agents. In addition, these chemotherapeutic agents have many 
adverse effects such as edema, nausea, rash and musculoskeletal pain. Therefore, new 
therapeutic agents -especially natural products due to their lower costs and also less side 
effects- are being investigated for their anticancer potentials. 
 
1.2. Resveratrol 
 
Resveratrol, 3,5,4’-trihydroxystilbene, is a natural product generated by various 
plants such as red grapes, peanuts, mulberries, blueberries, cranberries, etc., and 
approximately 70 other plants (Aggarwal, et al. 2004), by the enzyme stilbene synthase, 
in response to stress conditions such as UV irradiation, ozone exposure, heavy metal 
exposure, and pathogenic infection (Kundu and Surh 2008). Resveratrol is quite 
widespread in nature, and also its isomers and derivatives are recognized. UV 
irradiation and heat can make trans- form to turn into cis- form. Trans- form of 
resveratrol is more stable than cis- form, and it can be stored for months avoiding light 
(Aggarwal, et al. 2004).  
 
 
 
 
Figure 1.2. Chemical structure of resveratrol 
 
 
Resveratrol has been reported to have anti-inflammatory (Kang, et al. 2009), 
anti-angiogenic (Belleri, et al. 2005), anti-metastatic, cardioprotective, neuroprotective, 
apoptosis- and autophagy-inducer (Signorelli, et al. 2009), spermatogenesis-enhancer, 
OH
HO
OH
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and also chemosensitizer (Puissant, et al. 2008) and even radiosensitizer (Liao, et al. 
2005) effects. The inverse relationship between red wine consumption and protection 
from cardiovascular diseases is known as “French paradox” (Ulrich, et al. 2005). The 
anticancer effects of resveratrol were firstly reported by Jang et al. in which study 
showed the inhibition of initiation, promotion, and progression stages of carcinogenesis 
by resveratrol in 1997. After that, resveratrol attracted increasingly more attention by 
many cancer researchers due to investigate its molecular targets and functional 
mechanisms. Many in vivo studies showed that direct application of resveratrol to tumor 
tissue reduced tumor size, and some of the mechanisms of resveratrol action were 
clarified (Kundu and Surh 2008). Anticancer effects of resveratrol were mainly reported 
in prostate (Aziz, et al. 2006), breast (Scarlatti, et al. 2003), and colon (Delmas, et al. 
2003) cancers. Despite that, there are still many questionmarks in the mechanistic area 
of resveratrol. Therefore researchers are still studying with resveratrol to clarify the 
resveratrol mechanism (Kundu and Surh 2008). 
 
1.2.1. Regulatory Effects of Resveratrol on Cell Cycle 
Progression 
 
Resveratrol could arrest cell cycle at S phase, G1/S phase, and also G2/M phase 
transition in many cancer cells (Ulrich, et al. 2005). It induces p21WAF1 and p27KIP1 
and downregulates cyclins D1/D2/E, Cdks 2/4/6Cdc2 kinases and pRb which is 
hyperphosphorylated. Resveratrol also upregulates p21WAF1, p300/CBP, APAF1, and 
Bak, which are related with the p53 tumor suppressor gene activation, and 
downregulates Bcl-2 that has anti-apoptotic effects on cancer cells. In addition to p53-
dependent ways, resveratrol also induces p21WAF1 and cell cycle arrest by p53-
independent ways. In addition, it downregulates ribonucleotide reductase and DNA 
polymerase thus directly pevents DNA replication (Ulrich, et al. 2005). 
C-myc, one of the most expressed oncogene in many cancer cells, is also 
downregulated by resveratrol, and this is followed by the cell cycle arrest at the S phase 
(Zhang, et al. 2006). However, resveratrol inhibits Cdk1, the upstream target of myc 
oncogene, this inhibition in turn downregulates survivin, which is the target of Cdk1 in 
order to provide survival of cancer cells upregulating myc oncogene. Many in vivo and 
in vitro studies showed that resveratrol causes cancer cells to undergo apoptosis in myc-
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dependent manner. For this reason, Cdk1 inhibition by resveratrol treatment could be a 
new area for therapy of cancers overexpressing myc oncogene (Ulrich, et al. 2005). 
 
1.2.2. Regulatory Effects of Resveratrol on Apoptosis and 
Survival  
 
In many studies, resveratrol has been reported to cause cell cycle arrest and and 
apoptosis by regulating the expressions of the genes related with survival and apoptotic 
pathways (Kundu and Surh 2004). In many cancer cells, resveratrol induces apoptosis 
activating p53 tumor supressor gene (Laux, et al. 2004). Resveratrol causes the 
overexpression of Bim, Bax, Bak, Noxa, and PUMA, which are pro-apoptotic genes, 
and also the decrease in the expression levels of Bcl2, Bcl-XL, and Mcl-1, that are anti-
apoptotic genes, therefore influences the mitochondrial pathway of apoptosis (Athar, et 
al. 2009). Resveratrol also causes apoptosis through Fas/TRAIL pathway (Ishibashi and 
Ohtsuki 2008). Moreover, resveratrol sensitizes cancer cells developing resistance 
against therapeutic agents that cause apoptosis, by inhibiting transcription factors and 
anti-apoptotic genes, and by increasing the expression levels of apoptotic genes 
(Puissant, et al. 2008). Resveratrol also leads to the generation of ceramide, the second 
messenger of sphingomyelin pathway, therefore overcomes drug resistance, and causes 
apoptosis (Ulrich, et al. 2007). In radio-resistant DU145 prostate cancer cells, 
resveratrol causes apoptosis sensitizing these cells to radiotherapy due to induction of 
ceramide generation (Scarlatti, et al. 2007). In addition to prostate cancer cells, 
resveratrol has also been reported to mediate ceramide generation in breast and colon 
cancer cells (Scarlatti, et al. 2003, Sala, et al. 2003). 
Resveratrol induces not only apoptosis but also autophagocytosis. In 2004, 
Opipari et al. demonstrated that resveratrol had triggered autophagy in human ovarian 
cancer cells. In addition, Keng-Fu Hsu et al., in 2009, reported that resveratrol had 
induced autophagy in cervical cancer cells via cathepsin-L, which is a lysosomal 
endopeptidase playing an important role in protein catabolism. Moreover, resveratrol 
has been reported recently that it induces autophagy in CML cells through activating the 
function of AMPK, and causing the expression of p62/SQSTM1 mediated by JNK 
(Puissant and Auberger 2010). These findings suggest that resveratrol could induce cell 
death by autophagy rather than apoptosis in some cases, even in the cells that are 
resistant to chemotherapeutics targeting apoptosis. 
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1.2.3. Suppression of Invasion and Angiogenesis by Resveratrol  
 
A study reported that in human umbilical endothelial cells (HUVECs), 
resveratrol prevented cell growth by inhibiting MMP-2, one of the most important type 
IV collagenase that is an important factor of the basement membrane of whom 
degradation leads to metastasis, pursued by angiogenesis (Athar, et al. 2009). In these 
cells resveratrol prevents fibronectin and laminin to be attached by endothelial cells. In 
addition, many other studies showed that resveratrol decreases the expression levels of 
MMP-2 and MMP-9 in multiple myeloma and various types of endothelial cells. In the 
activation of MMP- 9 by DMBA or PMA (phorbol myristate acetate), resveratrol has 
been reported to inhibit NFκB and AP-1, or JNK, respectively, and also activate protein 
kinase C for the latter (Athar, et al. 2009). This inhibition of MMPs by resveratrol 
causes to suppression of invasion and metastasis. 
Moreover, resveratrol has been reported to suppress expression levels of VEGF, 
very important molecule for tumor development and angiogenesis in breast cancer cells 
(Garvin, et al. 2006). Resveratrol also inhibits ERK 1/2 and Akt, lowering the VEGF 
levels and the accumulation of hypoxia-induced HIF-1α protein (Wu, et al. 2008). 
Furthermore, resveratrol inhibits the activation of Src kinase, which is ROS-dependent, 
and also inhibits VE-cadherin tyrosine phosphorylation, that is important in providing 
stability to cell-cell junctions (Lin, et al.2003). By this way, it has been reported that 
resveratrol could successfully prevent angiogenesis induced by VEGF. Studies 
indicated that resveratrol suppresses the glioma development in rats via inhibiting 
angiogenesis (Athar, et al. 2009). 
 
1.2.4. Resveratrol Action in Cancer Inflammation 
 
Resveratrol has the ability to suppress the activity of cyclooxygenase-2 (COX-
2), the enzyme transforming free arachidonic acid to prostaglandins, resulting in DNA 
damage. In vivo studies have also indicated the ability of resveratrol in the suppression 
of COX-2 (Athar, et al. 2009). Resveratrol also regulates the activity of MKP5, which 
dephosphorylates mitogen-activated protein kinases (MAPKs). By dephosphorylation, 
MKP5 particularly inhibits protein kinases p38 and JNK that are stress-activated 
(Theodosiou, et al. 1999). 
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Inhibition of the activity of p38, which is important in prostate cancer due to its 
ability in facilitating proinflammatory responses, decreases NFκB activity, the levels of 
pro-inflammatory cytokines, and also COX-2, IL-6, and IL-8 expression (Nonn, et al. 
2007, Athar, et al. 2009). 
In MCF-7 and MDA-MB-231, human breast cancer cell lines, resveratrol-
mediated apoptosis occurs via the cooperation between COX-2 and ERK1/2 and AP-1. 
In these cells, ERK1/2 and AP-1 lead to the accumulation of agglomeration of COX-2. 
In this case, COX-2 is found with the p53, which is phosphorylated, and the co-activator 
of p53, p 300 (Tang, et al. 2006). With the apoptotic effect of resveratrol, the activity of 
ERK1/2 decreases resulting in the disintegration of COX-2/p53/p300 complex. 
Consequently, resveratrol could inhibit the progression of cancer via influencing the 
activity of inflammatory molecules. 
 
1.2.5. Effects of Resveratrol on Transcription Factors 
 
Inhibition of the activation of NFκB occurs through the inhibition of the 
phosphorylation of IKK and p65, the degradation of IκBα in many cancer cells (Athar, 
et al. 2009). In several cancer cells, NFκB inhibition by resveratrol also occurs by 
different mechanisms such as targeting TNF, H2O2, LPS or ceramide (Manna, et al. 
2000). Besides NFκB, resveratrol also decreases the expression levels of the genes 
regulated by NFκB, such as Bcl2, IL6, XIAP, VEGF, MMP-9, and c-IAP (Sun, et al. 
2006). In breast cancer cells, resveratrol has been reported as the inhibitor of metastasis, 
the process that specializes cancer cells mobile ability (Kundu and Surh 2004). 
Resveratrol inhibits the binding of AP-1 to DNA via decreasing the expression 
levels of c-FOS, one of many producers of AP-1. Resveratrol-mediated AP-1 inhibition 
can also occur via the suppression of c-Jun, and this is also related with the blockade of 
MEK-ERK1/2 signaling (Kundu, et al. 2006). 
Resveratrol-mediated p53 activation involves the serine 15-phosphorylation of 
this transcription factor, even in other words, “the guardian of the genome”, by ERK 
and p38 MAPK. It has been reported that resveratrol causes p53-dependent apoptosis by 
regulating Ras-MAPK signaling in thyroid cancer cells. Resveratrol also activates one 
of downstream molecules of p53, NAG-1. Resveratrol-mediated increase in NAG-1 
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expression levels decreases the ability of cancer cells for colony formation (Baek, et al. 
2002). 
 
1.2.6. Effects of Resveratrol on Cathepsin-D 
 
An aspartic endoprotease, cathepsin-D is an important mediator of apoptosis, 
and the translocation of mature cathepsin-D to the cytosol causes the release of 
cytochrome c from mitochondria and the activation of caspases 9 and 3. This 
relocalized cathepsin-D can also activates Bax, therefore apoptosis-inducing factor, AIP 
is released from the mitochondria, following the Bax activation. Resveratrol-induced 
cathepsin-D activation has been reported as one of the apoptotic mechanisms mediated 
by resveratrol. Resveratrol triggers cathepsin-D secretion in ER
+
 breast cancer cells in a 
dose-dependent fashion, but not in ER
-
 cells (Liaudet-Coopman, et al. 2006). 
 
1.2.7. Mitochondrial Effects of Resveratrol and Its Prooxidant Activity 
 
In normal cells, effects of resveratrol are related with the antioxidant activity and 
the protection of mitochondrial activity whereas in cancer cells, its effects are mostly 
related with the induction of apoptosis. 
Resveratrol inhibits complexI and F0F1-ATPase, which are the important 
ezymes for mitochondria (Zheng and Ramirez 1999). In addition, resveratrol collapses 
the redox homeostasis of mitochondria, and triggers apoptosis dependent to 
mitochondria (Dörrie, et al. 2001). However, resveratrol can also has prooxidant activity 
producing reactive intermediates. With this activity, resveratrol can causes cellular 
damage by oxidizing lipids, proteins, and DNA. ROS regulates p53 in a post-
translational manner, and triggers the breakdown of membrane permeability of 
mitochondria, and DNA fragmentation. Resveratrol protects DNA from damages 
mediated by ROS. In addition, in the presence of metal ions, resveratrol causes DNA 
degradation. Many studies indicated that in the presence of high levels of copper, which 
is characteristic for several cancer cells, resveratrol causes the ROS generation resulting 
in the loss of mitochondrial membrane potential, and finally apoptosis. Morever, 
treatment of p53
+
-cancer cells with subapoptotic doses of resveratrol causes to increase 
in the levels of H2O2 and superoxide anion (O2
-
), and also results in cell senescence that 
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is dependent to ATM. Such resveratrol-mediated cell senescence also includes p53, p38 
MAPK, and p21WAF1 activation (Athar, et al. 2009). 
Despite of these findings, exact mechanisms underlying resveratrol-induced 
apoptosis in CML cells have not been clearly identified yet. In order to enlighten this 
knife edge, bioactive sphingolipids have been studied in CML cells due to their 
potentials in regulating cellular processes.  
 
1.3. Bioactive Sphingolipids 
 
Sphingolipid family, a member of membrane lipids, have many important 
regulatory and structural roles in lipid bilayer. The sphingolipids ceramide, ceramide-1-
phosphate, glucosylceramide, galactosylceramide, shingosine, sphingosylphospho-
choline, and sphingosine-1-phosphate (S1P) are known as effector molecules of 
sphingolipid metabolism. These molecules have many important roles in several critical 
processes such as cell proliferation, inflammatory responses, migration, senescence, and 
also apoptosis (Ogretmen and Hannun 2004). 
Ceramide, the key molecule of sphingolipid family, can be generated in response 
to TNF-α, IL-1, Fas ligand, ionizing radiation, heat stress, oxidative stress, and 
chemotherapeutics (Ogretmen and Hannun 2004). Increasing intracellular levels of 
ceramide results in growth inhibition, differentiation, apoptosis, alteration of telomerase 
activity and telomere length, and senescence whereas increasing S1P levels results in 
the induction of cell proliferation, transformation, angiogenesis, and mobility, and also 
increased levels of glucosylceramide synthase (GCS) converting apoptotic ceramide 
into antiapoptotic glucosylceramide, makes several cancer cells multidrug resistant 
(Ogretmen and Hannun 2004). 
 
 
Figure 1.3. Chemical structure of ceramide 
(Source: Hannun and Obeid 2008) 
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1.3.1. Bioactive Sphingolipid Metabolism 
 
Generally, ceramide is produced via two different mechanisms. One mechanism 
is generation of ceramide by the de novo pathway, and the other one is the generation of 
ceramide by the lipid hydrolysis, such as sphingomyelin (SM) hydrolysis. In de novo 
pathway, serine condenses with palmitoyl-CoA by serine palmitoyl transferase to 
generate 3-ketodihydrosphingosine. 3-keto-dihydrosphingosine is reduced, and 
dihydrosphingosine (sphinganine) is formed. Then, sphinganine is N-acylated by 
dihydroceramide (dhCeramide) synthases in order to produce dhCeramide or ceramide. 
In the hydrolytic pathway, sphingomyelinase hydrolizes sphingomyelin delivering 
phosphocholine and ceramide. Ceramide kinase phosphorylates ceramide in order to 
generate ceramide-1-phosphate (Sugiura, et al. 2002). 
Ceramide can be converted into sphingosine by ceramidases (El Bawab, et al. 
2002), sphingosine is in turn phosphorylated by sphingosine kinases in order to form 
sphingosine-1-phosphate (S1P). S1P is then converted into sphingosine by 
phospahatases or by the enzyme lyase, S1P is converted into ethanolamine-1-phosphate 
and a C16-fatty-aldehyde (Ogretmen and Hannun 2004). 
 
1.3.2. LASS Genes as Ceramide Synthases 
 
LASS genes were firstly investigated in yeasts and called as longevity assurance 
genes (lag1). In mammals, de novo ceramide synthesis is conducted by LASS 
(longevity assurance homologues) genes (LASS 1-6). Each of these six genes generates 
ceramides in different lengths. While LASS1 generates C18:ceramide, LASS2 and 
LASS4 generate C22:- and C24:ceramides, respectively. LASS5 and LASS6 generate 
shorter-chain ceramides such as C14:- and C16:ceramide, respectively. Despite of 
having lower specificity to fatty acyl-CoAs, LASS3, however, generates C18:-, C22:-, 
and C24:ceramides (Teufel, et al. 2009). These different-length-ceramides may have 
different functions. For example, while C16:ceramide is important in the induction of 
apoptosis in LNCaP cells and hepatocytes, C18:ceramide is important in head and neck 
squamous cell carcinomas (Teufel, et al. 2009). 
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Figure 1.4. Pathways of sphingolipid metabolism 
(Source: Ogretmen and Hannun 2004) 
 
 
1.3.3. Compartmentalization of Sphingolipids 
 
In sphingolipid metabolism, enzymatic reactions are delivered into distinct 
cellular compartments. De novo ceramide synthesis occurs on the cytosolic side of the 
endoplasmic reticulum (ER) and in ER-associated membranes. Sphingomyelin and 
glucosylceramide synthesis occurs in the Golgi apparatus. Ceramide can be transported 
from ER to the Golgi apparatus by two ways. In the first way, ceramide in the form of 
sphingomyelin, is transported by the activity of the ceramide transfer protein, CERT. In 
the other way, ceramide in the form of glucosylceramide is transported by vesicules. In 
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mitochondria, ROS are generated, and these ROS activate neutral sphingomyelinase (N-
SMase), which generates ceramide. This ceramide activates PP1 and PP2A, that are 
ceramide-activated protein phosphatases. PP2A dephosphorylates and inactivates 
antiapoptotic proteins. Also, PP1 activates Bid. In lysosomes, acid sphingomyelinase 
generates ceramide. This ceramide activates Cathepsin-D and Bid, and then activates 
caspases -9 and -3. In addition, ceramide can be converted into sphingolipids by the 
action of acid ceramidase. In the plasma membrane, ceramide is generated in the lipid 
rafts, and this generated ceramide affects important signaling pathways (Hannun and 
Obeid 2008).  
 
 
 
 
Figure 1.5. Ceramide compartmentalization 
(Source: Ogretmen and Hannun 2004)  
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1.3.4. Roles of Sphingolipid Metabolism in Cancer 
 
Understanding the molecular identifications of the enzymes that play roles in 
sphingolipid metabolism has provided the observation of molecular pathways 
occupying in this metabolism. In addition, studies showed that these enzymes occupy 
different cellular compartments. Such compartmentalized localization of enzymes 
indicates the complexity of the pathways in sphingolipid metabolism. Moreover, levels 
of these enzymes show differences in cancer cases, demonstrating that enzymes in 
sphingolipid metabolism have different functions in carcinogenesis. Many studies 
showed that ceramide levels and cancer progression are correlated inversely whereas 
sphingosine kinase-1 levels are related with cancer progression in several cancer cells 
(Ogretmen and Hannun 2004, Saddoughi, et al. 2008). 
 
 
 
 
Figure 1.6. Changes in balance between ceramide and S1P in response to therapy 
(Adapted from: Saddoughi, et al. 2008) 
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1.3.5. Apoptotic Effects of Ceramide 
 
Several studies showed that ceramide is related with the apoptotic inducers such 
as TNF-α, FAS/FASL, hypoxia, and DNA damage in many cancer cells (Pettus, et al. 
2002). These apoptotic inducers provide ceramide to accumulate in cancer cells via 
different ways of ceramide metabolism. Studies also showed that the generation of C16-
ceramide in response to apoptotic signals occurs via de novo pathway. In addition, some 
chemotherapeutic agents such as daunorubicin, etoposide, gemcitabine, and FAS ligand 
causes de novo generation of C16-ceramide (Ogretmen and Hannun 2004, Saddoughi, et 
al. 2008). 
 
 
 
 
Figure 1.7. Downstream targets of ceramide 
(Source: Ogretmen and Hannun 2004) 
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Generation of ceramide by acid sphingomyelinase (A-SMase) also plays roles in 
apoptosis. Generally, ionizing radiation and ultraviolet A (UVA) cause an increase in 
ceramide levels through acid sphingomyelinase activity. Morover, TNF-α is also 
responsible for generation of ceramide via A-SMase, resulting in cathepsin D activation, 
which is an endolysosomal aspartate protease. This activation of cathepsin D, in turn, 
results in the activation of caspase-9 and caspase-3, which is Bid-mediated. Besides A-
SMase, neutral sphingomyelinase (N-SMase) also plays roles in ceramide generation 
and thus ceramide-mediated apoptosis. According to studies, N-SMase-activated 
apoptotic pathways include TNF in many cancer cells, and also N-SMase requires 
reactive oxygen species (ROS) for activation, indicating ceramide action in response to 
ROS-mediated DNA damages (Ogretmen and Hannun 2004).  
Furthermore, ceramidases (CDases) also perform in the regulationof ceramide 
levels. In many cases, nitric oxide (NO) degragades neutral CDases, resulting in the 
accumulation of ceramide. Subsequently, this ceramide accumulation results in 
apoptosis (Franzen, et al. 2002). 
Some studies indicated that ceramide generation in the same cell type can be 
controlled by more than one mechanism of ceramide metabolism. For example, in TNF-
treated MCF-7 cells, both de novo pathway and N-SMase pathway are activated 
autonomously. Ligand binding to FAS receptor also activates the pathways A-SMase, 
N-SMase, and de novo. Distinct ceramide-induced cell death pathways are activated by 
every one of these mentioned pathways (Luberto, et al. 2002, Dbaibo, et al. 2001). 
 
1.3.6. Ceramide Action in Quiescence and Senescence 
 
In some cases, ceramide arrests cells at G0/G1 phase. TNF treatment induces 
dephosphorylation of retinoblastoma (Rb) by ceramide via PP1 activation (Dbaibo, et 
al. 1995). In addition to Rb, ceramide dephosphorylates and inactivas Cdk2, cyclin-
dependent kinase. Ceramide also upregulates p21WAF1 and p27KIP1 in some types of 
cancer. Human N-SMase 2 regulates cell cycle progression and cell growth by 
providing the activation of ceramide-mediated growth repression (Ogretmen and 
Hannun 2004, Lee, et al. 2000). 
Ceramide also induces senescence via dephosphorylating Rb, repressing protein 
kinase C, regulating growth factor signalling, and inhibiting CDKs, diacylglycerol, and 
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phospholipase D. In addition, ceramide can induce senescence through inhibiting the 
active expression of telomerase in many cancer cells (Ogretmen and Hannun 2004). 
 
1.3.7. Effects of S1P in Transformation, Proliferation, Apoptotic 
Inhibition, Angiogenesis, and Inflammation 
 
Many studies showed that, in contrast to ceramide, increased levels of 
sphingosine 1-phosphate is related with cell proliferation and suppression of apoptosis, 
which is especially induced by ceramide (Ogretmen and Hannun 2004, Cuvilier, et al. 
1996). In several cancer cells, it has been reported that S1P increases invasive properties 
and carcinogenesis potential (Van Brocklyn, et al. 2003). 
S1P can induce the formation of blood vessels in many cancer cells through 
VEGF signalling, which in turn induceses RAS and MAPK signalling pathways. S1P 
activates S1P receptors and regulates a family of GTPases, RHO, providing endothelial 
cells to migrate, and also resulting in the reconstruction of cytoskeleton, and inhibition 
of apoptosis (Liu, et al. 2001, Wu, et al. 2003). 
Some cytokines such as TNF-α and interleukin1 (IL-1) have been reported to 
activate S1P-SK1 pathway, and cause the development of inflammatory responses. 
Inflammatory functions of S1P involves the agglomeration of S1P by the induction of 
SK1, which activates subsequently NFκB. S1P also induces COX-2 and prostaglandin 
E2 (PGE2), resulting in the inflammation (Xia, et al. 1998). 
 
1.3.8. Sphingolipid Use as Anticancer Therapy 
 
Summarily, ceramide is a pro-apoptotic molecule whereas S1P converted from 
ceramide by the enzyme SK1 is anti-apoptotic, and promotes carcinogenesis, and also 
causes the genes which are responsible for synthesizing ceramide, and by GCS and SK-
1 that convert ceramide to glucosylceramide, and sphingosine-1-phosphate (S1P), 
respectively. Modulation of intracellular levels of these sphingolipids could open a new 
road in cancer therapy. Moreover, alteration of these levels could circumvent multidrug 
resistance, increase the efficiency of chemotherapeutic molecules, and also provide 
defence mechanism to normal cells from toxic substances (Ogretmen and Hannun 
2004). 
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1.4. Aim of the Study 
 
Since the incidence of CML is increasing day by day and emerging of resistance 
cases of the patients with CML against chemotherapeutic agents is raising, new 
therapeutic approaches are being investigated nowadays. Resveratrol is the centre of 
interest due to its potential in repressing the phases cancer initiation, promotion, and 
progression. Although potential benefits of resveratrol are known, the molecular 
mechanisms underlying its apoptotic effects is not still completely understood. 
Furthermore, ceramides are also the centre of interest due to their strong 
apoptotic potentials. As known, while ceramide is an apoptotic molecule and leads to 
many antiproliferative processes, S1P and GCS are highly antiapoptotic and lead to the 
processes related with cell survival. 
Under the light of these informations, we aimed to investigate the molecular 
mechanisms related with the apoptotic effects of resveratrol, and its possible effects on 
sphingolipid metabolism in K562 human chronic myeloid leukemia cells. In addition, 
we intended to determine the possible synergistic effects of resveratrol and ceramide by 
applying exogenous ceramide, and also by manipulating the intracellular ceramide 
levels via treating the cells with PDMP, the inhibitor of glucosylceramide synthase that 
converts apoptotic ceramide into antiapoptotic glucosylceramide, and SK1 inhibitor 
inhibiting the enzyme sphingosine kinase-1, the converter of apoptotic ceramide to 
antiapoptotic S1P.  
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1. Chemicals  
 
Resveratrol was obtained from Sigma Aldrich (USA). The stock solution of 
resveratrol was dissolved in dimethylsulfoxide (DMSO) at a concentration of 10 
mmol/ml, stored at -20 
o
C, and diluted in cell culture medium. C8:ceramide, PDMP (1-
phenyl-2-decanoylamino-3-
 
morpholino-1-propanol) that is GCS inhibitor, and SK-1 
inhibitor were obtained from Cayman Chemicals (USA), and dissolved in DMSO. 
Penicillin-streptomycin, RPMI1640, and fetal bovine serum (FBS) were obtained from 
Invitrogen (Paisley, UK). Total RNA isolation kit was obtained from Macherey-Nagel 
(Germany). Reverse transcriptase (Moroney Murine Leukemia Virus Reverse 
Transcriptase), Taq DNA polymerase, and primers were obtained from Fermentas 
(USA). Bradford dye, and Coomasie blue, bovine serum albumine (BSA), trypan blue 
solution, β-mercaptoethanol, dimethylsulfoxide (DMSO), and agarose were obtained 
from Sigma (USA). DNA ladder, gel loading dye, and dNTP set were obtained from 
Fermentas (USA). Caspase-3 colorimetric assay kit was obtained from BioVision 
(USA). APO LOGIX JC-1 assay kit was obtained from Cell Technology (USA).  
 
2.2. Cell Line, Culture Conditions, and Maintenance 
 
Human K562 CML cells were obtained from German Collection of 
Microorganisms and Cell Cultures (Germany). These Ph (+) K562 human CML cells 
were cultured in RPMI1640 growth medium containing 1% L-glutamine, 10% fetal 
bovine serum, and 1% penicillin-streptomycin at 37 °C in 5% CO2. Medium was 
refreshed in every 2 days. In order to passage the cells, whole cell suspension is taken 
into a falcon tube, and then centrifuged at 1000 rpm for 10 minutes. After cenrifugation, 
the supernatant was removed from the tube, and the rest pellet was dissolved in 10 ml of 
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medium. This cell suspension was then transferred into a sterile 75 cm
2
-tissue culture 
flask containing 10 ml of growth medium. 
 
2.3. Thawing the Frozen Cells 
 
Cells were removed from the frozen storage at -80 
o
C and then immediately 
thawed in a water bath at 37 
o
C in order to acquire the highest percentage of viable 
cells. When the ice crystals melted, the content was transferred into 25 cm
2
- tissue 
culture flask containing 5 ml of RPMI1640 medium, and incubated overnight at 37 °C 
in 5% CO2. After incubation, cells were passaged as mentioned before. 
 
2.4. Measurement of Cell Viability 
 
In order to measure the viabilities of cells, 30 µl of cells were mixed with 30 µl 
of trypan blue dye which is an important dye using in distinguishing dead cells from 
alive cells under microscopy. When cells were treated with trypan blue dye, viable cells 
would not permeate this dye whereas dead cells would permeate because of their broken 
cell membranes. Therefore under a microscope, while dead cells would be stained blue, 
viable cells would not. By this way, cells were counted under microscope by using 
hemocytometer and then the percentage of unstained cells was calculated. Before each 
experiment, cell viability assay was conducted. 
 
2.5. Measurement of Cell Growth by XTT Assay 
 
The IC50 values (drug concentration that inhibits cell growth by 50%) of 
resveratrol and C8:ceramide, and the IC10 values (drug concentration inhibits cell 
growth by 10%) of PDMP, and SK-1 inhibitor were determined by XTT cell 
proliferation assay. In short, 2x10
4
 cells/100 µl/well were seeded into 96-well plates 
containing 100 µl of the growth medium in the absence or presence of increasing 
concentrations of resveratrol, C8:ceramide, PDMP, or SK-1 inhibitor and then 
incubated at 37 °C in 5% CO2. After 72 h incubation period, cells were treated with 50 
µl XTT for 4 h. Then, the plates were read under 492 nm wavelengths by Elisa reader 
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(Thermo Electron Corporation Multiskan Spectrum, Finland). Finally, IC50 values of 
resveratrol and C8:ceramide, and IC10 values of PDMP and SK-1 inhibitor were 
calculated according to the cell proliferation plots. 
In order to determine the possible synergistic effects of resveratrol in 
combination with C8:ceramide, PDMP, or SK-1 inhibitor, 2x10
4
 K562 cells were 
seeded into each well of 96-well plate containing 100 µl of the growth medium. Then 
combinations of resveratrol with IC50 value of C8:ceramide or IC10 values of PDMP or 
SK-1 inhibitor were applied onto the cells. After 72 h incubation, the cells were treated 
with 50 µl of XTT mixture for 4 h and the plates were read under 492 nm wavelengths 
by Elisa reader (Thermo Electron Corporation Multiskan Spectrum, Finland). 
 
2.6. Evaluation of Apoptosis  
 
2.6.1. Caspase-3 Colorimetric Assay 
 
Changes in caspase-3 enzyme activity of the cells, as an important sign of 
apoptosis, were examined by caspase-3 colorimetric assay kit (BioVision Research 
Products, USA). This assay is based on spectrophotometric detection of the 
chromophore p-nitroanilide (pNA) after cleavage from the labeled substrate DEVD-
pNA that can be recognized by caspases. 
In short, the cells (1x10
6 
cells/2 ml/well), induced to undergo apoptosis, were 
collected by centrifugation at 1000 rpm for 10 min. The cells were lysed by adding 50 
µl of chilled Cell Lysis Buffer and incubated on ice for 10 min before centrifugation at 
10000 g for 1 min. Supernatants were transferred to new eppendorf tubes and the 
reaction mixture was prepared in 96-well plates by adding 50 µl of 2X Reaction Buffer 
(containing 10 mM DTT), 50 µl of sample, and 5 µl of DEVD-pNA substrate, and then 
incubated for 2 h at 37 °C in carbondioxide incubator. At the end of this period, the 
plate was read under 405 nm wavelengths by Elisa reader (Thermo Electron 
Corporation Multiskan Spectrum, Finland). 
The absorbance values are normalized to protein concentrations determined by 
Bradford assay. In this assay, protein samples were diluted by the ratios 1:25, 1:50, and 
1:100. Then 90 µl of each sample were added to 96-well plates, containing 10 µl of 
Bradford reagent. Bradford reagent uses Coomassie blue G-250. Without protein, the 
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solution is red-brown in its acidic solution. When protein binds, the pKa of the dye 
shifts causing the dye to become blue. Finally, the dye within the plates was measured 
at 595 nm by Elisa reader.  
 
2.6.2. JC-1 Mitochondrial Membrane Potential 
 
We have also examined the loss of MMP, another important sign of apoptosis, in 
response to resveratrol, C8:ceramide, PDMP, and SK-1 inhibitor or combinations of 
resveratrol with the others in K562 cells by the APO LOGIX JC-1 Mitochondrial 
Membrane Potential Detection Kit (Cell Technology, USA). This kit uses JC-1, a 
unique cationic dye, to signal the loss of the MMP. JC-1 accumulates in the 
mitochondria which stain red in non-apoptotic cells while in apoptotic cells, the MMP 
collapses, and thus the JC-1 remains in the cytoplasm as a monomer that stains green 
under fluorescent light. 
Briefly, the cells (1x10
6 
cells/2 ml), induced to undergo apoptosis, were 
collected by centrifugation at 1000 rpm for 10 min. Supernatants were removed, 500 µl 
of JC-1 dye was added onto the pellets, and the cells were incubated at 37°C in 5% CO2 
for 15 min. Then, they were centrifuged at 1000 rpm for 5 min and 2 ml of assay buffer 
was added onto the pellets. After centrifugation at 1000 rpm for 5 min all pellets were 
resuspended with 500 µl assay buffer and 150 µl from each of them was added into the 
96-well plate. The aggregate red form has absorption/emission maxima of 585/590 nm 
and the monomeric green form has absorption/emission maxima of 510/527 nm. The 
plate was read in these wavelengths by fluorescence Elisa reader (Thermo Varioskan 
Spectrum, Finland). At the end, green/red (510/585) values were calculated in order to 
determine the changes in MMP. 
In addition, K562 cells were treated with increasing concentrations of resveratrol 
in combinations with C8:ceramide, PDMP, or SK-1 inhibitor. For this purpose, K562 
cells (1x10
6 
cells/2 ml) were seeded into 6-well plates and then treated with IC50 value 
of C8:ceramide or IC10 values of PDMP or SK-1 inhibitor. After incubating the plates 
for 18 h at 37 °C in 5% CO2, increasing concentrations of resveratrol were applied into 
these plates. After 72 h incubation, the assay procedure mentioned above was executed.  
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2.7. Total RNA Isolation and RT-PCR 
 
Total RNAs of K562 cells, treated with increasing concentrations of resveratrol, 
were extracted using a Ribolock RNA isolation kit (Macherey-Nagel, Germany) as 
described by the manufacturer. Concentrations of isolated RNAs were measured by 
Nanodrop ND-1000 (260/280 and 260/230 ratios). 1 µg of each total RNA was reverse 
transcribed using reverse transcriptase (Moroney Murine Leukemia Virus Reverse 
Transcriptase, Fermentas, USA). After 50 min of incubation at 42 °C, the reactions were 
stopped at 95 °C for 5 min. The resulting total cDNAs were then used in PCR to 
measure the mRNA levels of LASS2, LASS4, LASS5, LASS6, SK1, GCS and β-actin. 
The mRNA levels of β-actin were used as internal positive control.  
 
 
Table 2.1. Primer sequences used in this study 
 
LASS2-F (5’-GCTGGAGATTCACATTTTAC-3’) 
LASS2-R (5’-GAAGACGATGAAGATGTTGT-3’) 
LASS4-F (5’-TGCTGTCCAGTTTCAACGAG-3’) 
LASS4-R (GAGGAAGTGTTTCTCCAGCG-3’) 
LASS5-F (5’-TCCTCAATGGCCTGCTGCTG-3’) 
LASS5-R (5’-CCCGGCAATGAAACTCACGC-3’) 
LASS6-F (5’-CTCCCGCACAATGTCACCTG-3’) 
LASS6-R (5’-TGGCTTCTCCTGATTGCGTC-3’) 
SK1-F (5’-CCGACGAGGACTTTGTGCTAAT-3’) 
SK1-R (5’-GCCTGTCCCCCCAAAGCATAAC-3’) 
GCS-F (5’-ATGACAGAAAAAGTAGGCT-3’) 
GCS-R (5’-GGACACCCCTGAGTGGAA-3’) 
β-actin-F (5’-CAGAGCAAGAGAGGCATCCT-3’) 
β-actin-R (5’-TTGAAGGTCTCAAACATGAT-3’) 
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Table 2.2. Ingredients for cDNA synthesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.3. Ingredients of PCR solutions for LASS2, LASS4, LASS5, GCS, SK1, and β-
actin genes 
 
 
Reaction Mixture 
 
Amounts for LASS2, LASS4, 
LASS5, LASS6, GCS, SK1, β-actin 
(µl) 
PCR-grade water 30.7 
Reaction buffer (10X) 5 
MgCl2 (25mM) 5 
dNTP (2mM) 5 
Primer forward (20 pmol/µl) 1 
Primer reverse (20 pmol/µl) 1 
cDNA 2 
Taq DNA Polymerase 0.3 
Total volume 50 
 
Ingredients Amount (µl) 
RNase-free water 2.9 
Total RNA (5µg) 5 
10X Buffer 4 
Random Hexamer Primer (0.5 µg/l) 0.7 
RNase Inhibitor 0.7 
MgCl2 (25mM) 4 
dNTP (10mM) 2 
Moloney Murine Reverse 
Transcriptase 
(200 U/µl) 
0.7 
Total volume 20 
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Table 2.4. Amplification conditions for LASS2 
 
Steps Temperature (
o
C) Duration (min.) 
Initial Denaturation 94 5 
Denaturation 94 1 
Annealing 54 1 
Extension 72 1 
Final Extension 72 5 
 
 
Table 2.5. Amplification conditions for LASS4 
 
Steps Temperature (
o
C) Duration  
Initial Denaturation 94 5 min 
Denaturation 94 30 s 
Annealing 57 30 s 
Extension 72 45 s 
Final Extension 72 5 min 
 
 
Table 2.6. Amplification conditions for LASS5 and LASS6 
 
Steps Temperature (
o
C) Duration (min) 
Initial Denaturation 94 5  
Denaturation 94 1  
Annealing 65 1 
Extension 72 1 
Final Extension 72 5 
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Table 2.7. Amplification conditions for GCS and SK1 
 
Steps Temperature (
o
C) Duration (min.) 
Initial Denaturation 94 5 
Denaturation 94 2 
Annealing 53 2 
Extension 72 2 
Final Extension 72 5 
 
 
Table 2.8. Amplification conditions for β-actin 
 
Steps Temperature (
o
C) Duration (min.) 
Initial Denaturation 94 5 
Denaturation 94 1 
Annealing 53 1 
Extension 72 1 
Final Extension 72 5 
 
 
After running the PCR products on agarose gel electrophoresis, quantification of 
expression levels of the genes were performed by Quantity One-1D-Gel-Imaging 
programme (BIORAD). The results were normalized to β-actin levels.  
 
2.8. PCR Array 
 
In order to investigate the molecular mechanisms underlying resveratrol-induced 
cell deaths, in this study we also used Human Cancer Pathway Finder RT
2
 Profiler PCR 
Array System (SABiosciences Corporation, USA). With the help of  this array, we 
analyzed the expression profiles of 84 genes which play important roles in cancer 
initiation, promotion, progression, and resistance. 
Total RNAs of K562 cells, treated with 50- and 500 µM of resveratrol, were 
extracted using High Pure RNA isolation kit (Roche Diagnostics GmbH, Germany) as 
described by the manufacturer. RNA concentration were measured by Nanodrop ND-
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1000 (260/280 and 260/230 ratios). 5 µg of each total RNA was treated with Genomic 
DNA Elimination Mixture provided by RT
2
 First Strand Kit (SABiosciences 
Corporation, USA). After an incubation period for 5 min at 42 °C, samples were chilled 
on ice for 1 min. In the course of this incubation period, RT coctail was prepared as 
described by the manufacturer. Then, after chilling on ice, 10 µl of RT coctail was 
added to each 10-µl  Genomic DNA Elimination Mixture. Samples were incubated at 42 
o
C for 15 min and then the reaction was stopped by heating at 95 
o
C for 5 min, and by 
this way, cDNAs were acquired. Then, 91 µl of H2O was added to each 20-µl of cDNA 
synthesis reaction. Afterwards, expression profiles of the genes which play important 
roles in cell-cycle control, DNA damage repair, apoptosis, cell senescence, signal 
transduction and transcription, adhesion, angiogenesis, and also invasion and metastasis 
were analyzed by RT
2
 Profiler PCR Array, which is a reliable and sensitive gene 
expression profiling technology.  
 
 
Table 2.9. Ingredients of PCR Array Experimental Coctail 
 
    
 
 
 
 
 
 
 
After preparing this coctail, 25 µl of experimental coctail was added to each well 
of the PCR Array, which is a PCR plate preloaded with validated real-time PCR primers 
for a panel of pathway-focused genes.  
Afterwards, PCR Array plates were sealed with the adhesive film. Then, one 
plate was placed in real-time thermal cycler (Roche LightCycler 480, Germany), and 
reaction was executed. 
 
 
 
Plate Format 96-well 
2X SABiosciences RT
2 
qPCR Master Mix 1350 µl 
Diluted First Strand cDNA Synthesis Reaction 102 µl 
H2O 1248 µl 
Total Volume 2700 µl 
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Table 2.10. Two-step cycling program executed in Roche LightCycler 480 
 
Cycles Duration Temperature 
1 10 min 95 
o
C 
45 
15 s 95 
o
C 
1 min 60 
o
C 
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CHAPTER 3 
 
RESULTS AND DISCUSSION 
 
3.1. XTT Cell Proliferation Assay on K562 Cells 
 
3.1.1. Cytotoxic Effects of Resveratrol, C8:Ceramide, PDMP or SK-1 
Inhibitor on Human K562 Chronic Myeloid Leukemia Cells  
 
In order to examine antiproliferative effects of resveratrol, C8:ceramide, PDMP, 
or SK-1 inhibitor on human K562 cells, the cells were incubated with increasing 
concentrations of the agents for 72 h and XTT cell proliferation assay was conducted. 
The results showed that there were dose-dependent decreases in cell proliferation as 
compared to untreated controls. IC50 value of resveratrol (Figure 3.1), and C8:ceramide 
(Figure 3.2), or IC10 values of PDMP (Figure 3.3) and SK-1 inhibitor (Figure 3.4) were 
calculated from cell proliferation plots and were found to be 80-, 60-, 20-, and 7 µM, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Cytotoxic effects of resveratrol on K562 cells 
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Figure 3.2. Cytotoxic effects of C8:Ceramide on K562 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Cytotoxic effects of PDMP on K562 cells 
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Figure 3.4. Cytotoxic effects of SK-1 inhibitor on K562 cells 
 
 
3.1.2. Cytotoxic Effects of Resveratrol in Combination with 
C8:Ceramide, PDMP or SK-1 Inhibitor on K562 Cells 
 
In order to examine the possible synergistic cytotoxicity, the cells were exposed 
to increasing concentrations of resveratrol from 1- to 100 µM together with 60 µM 
C8:ceramide, or 20 µM PDMP, or 7 µM SK-1 inhibitor. Combination of 1-, 50-, and 
100 µM of resveratrol with 60 µM C8:ceramide decreased proliferation of K562 cells 
from 87-, 88-, and 89%, while resveratrol application by itself decreased cell 
proliferation 8-, 43-, and 59%, respectively (Figure 3.5). The same doses of resveratrol 
in combination with 20 µM PDMP or 7 µM SK1 inhibitor decreased cell proliferation 
29-, 55-, and 68% or 23-, 54-, and 73%, respectively (Figure 3.5). This data demonstrate 
that resveratrol in combination with C8:ceramide, PDMP or SK-1 inhibitor has 
significant cytotoxic effect on human K562 cells. 
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Figure 3.5. Cytotoxic effects of Resveratrol in combination with C8:ceramide, or 
PDMP, or SK-1 inhibitor on K562 cells 
 
 
3.2. Evaluation of Apoptosis in K562 Cells 
 
3.2.1. Synergistic Apoptotic Effects of Resveratrol Together with 
C8:Ceramide, PDMP or SK-1 Inhibitor on K562 Cells 
 
In order to determine the mechanisms of resveratrol in the inhibition of cell 
proliferation, we examined whether resveratrol, C8:ceramide, PDMP or SK-1 inhibitor 
induces apoptosis in addition to examining the synergistic apoptotic effects. Apoptosis 
was evaluated by measuring the changes in caspase-3 enzyme activity and loss of 
mitochondrial membrane potential. As shown in Figure 3.6, there were 1.12-, and 1.21-
fold increases in caspase-3 enzyme activity in response to 1-, and 10 µM resveratrol, 
respectively. Coadministration of 60 µM C8:ceramide or 20 µM PDMP or 7 µM SK-1 
inhibitor with the same doses of resveratrol increased caspase-3 enzyme activity 2.11-, 
and 3.1- or 1.29-, and 1.87- or 2.36 and 2.49-fold, respectively. The same 
concentrations of C8:ceramide, PDMP and SK-1 inhibitor caused 1.44-, 1.22-, and 1.83-
fold increases in enzyme activity, respectively. 
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Figure 3.6. Changes in caspase-3 enzyme activity in response to resveratrol, 
C8:ceramide, PDMP, or SK-1 inhibitor alone, or their combinations 
 
 
In order to confirm caspase-3 enzyme activity results and examine the roles of 
mitochondria in resveratrol-induced apoptosis, we also determined the loss of 
mitochondrial membrane potential. The results were in agreement with our previous 
data and have shown that all these chemicals induce apoptosis through inducing loss of 
MMP. Combination of resveratrol with C8:ceramide, PDMP or SK-1 inhibitor caused 
loss of MMP synergistically as compared to any agent alone and untreated control 
group (Figure 3.7). As shown in Figure 3.7, there were 1.46-, 1.58- and 88.98- or 1.32-, 
and 1.32-fold increases in changes of mitochondrial membrane potentials in response to 
1-, and 10 µM resveratrol, and 60 µM C8:ceramide or 20 µM PDMP and 7 µM SK-1 
inhibitor alone treated K562 cells, respectively, as compared to untreated controls. 
Coadministration of 60 µM C8:ceramide or 20 µM PDMP or 7 µM SK-1 inhibitor with 
the same doses of resveratrol increased the changes of mitochondrial membrane 
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potentials 205.0- and 274.87-, 2.77- and 2.92- or 3.6- and 4.06-fold, respectively, as 
compared to untreated controls. 
 
 
 
 
Figure 3.7. Changes in mitochondrial membrane potantial in response to resveratrol, 
C8:ceramide, PDMP, or SK-1 inhibitor alone, or their combinations 
 
 
3.3. Estimation of PCR Results 
 
3.3.1. Effects of Resveratrol on Ceramide-Metabolizing Genes in K562 
Cells  
 
In order to determine whether ceramide metabolizing genes are involved in 
resveratrol-induced apoptosis, K562 cells were treated with increasing concentrations of 
resveratrol (1-, 10-, 20-, and 50 µM) and expression levels of LASS2, LASS4, LASS5, 
LASS6, GCS, SK-1 and ß-actin were determined by RT-PCR. As shown in Figure 3.8 
and table 3.1, resveratrol decreased expression levels of GCS and more significantly of 
SK-1 genes. On the contrary, expression levels of LASS2, and LASS5, and to a lesser 
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extent LASS4, and LASS6 were increased in response to resveratrol as compared to 
untreated controls, and normalized to ß-actin levels (Figure 3.8, Table 3.1). 
 
 
 
 
Figure 3.8. Expression levels of LASS2, -4, -5, -6, and GCS, SK-1 genes in response to 
increasing concentrations of resveratrol 
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Table 3.1. Quantification of expression levels of the genes in response to increasing 
concentrations of resveratrol 
 
 GCS SK-1 LASS2 LASS4 LASS5 LASS6 
Control 100 100 100 100 100 100 
1 83 69 91 101 73 105 
10 82 41 174 102 57 109 
20 92 43 182 121 77 129 
50 83 35 191 121 188 131 
 
 
3.4. Assessment of Human Cancer Pathway Finder PCR Array Results 
 
In order to analyze the genes regulated by resveratrol-induced apoptosis, K562 
cells were treated with increasing concentrations of resveratrol (10-, and 50 µM) and 
expression levels of 84 genes involved in cell cycle control and DNA damage repair, 
apoptosis and cell senescence, signal transduction molecules and transcription factors, 
adhesion, angiogenesis, and also invasion and metastasis were determined by Human 
Cancer Pathway Finder PCR Array. As shown in Figure 3.9 and 3.10, there were 
increases more than 4-fold in expression levels of 25 and 52 genes among 84 genes in 
response to 10- and 50 µM resveratrol. Moreover, there was a decrease less than 4-fold 
in only one gene (Myc) in response to 50 µM resveratrol (Figure 3.9 and 3.10). These 
genes changed significantly were found to be related with tumor suppressing, apoptosis, 
metastasis, and/or angiogenesis. As compared with untreated control group, 5 
housekeeping genes, 3 reverse transcription controls, and 3 positive PCR control 
groups, expression levels of tumor suppressor SERPINB5, and apoptosis-triggering 
TNFRSF25, FAS, GZMA genes were found to be the most changed ones among these 
84 genes. 
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Table 3.2. Plate layout of PCR Array 
 
 
 
 
 
 
Figure 3.9. Changes in expression levels of 84 genes in response to 10 µM resveratrol 
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Figure 3.10. Changes in expression levels of 84 genes in response to 50 µM resveratrol 
 
 
The tumor suppressor SERPINB5 gene expression level was increased 62.33-
fold whereas the expression levels of tumor necrosis factor receptor (TNFRSF25), 
fibroblast growth factor receptor (FGFR), ependymin-related protein (EPDR1), proto-
oncogenic mesenchymal epithelial transition (MET), FAS, and also metastasis 
suppressor gene (MTSS) were increased 61.35-, 47.83-, 44.33-, 43.24-, 40.82-, 39.47-
fold, respectively. In addition, TEK endothelial tyrosine kinase, granzyme A, integrin 
α1 (ITGA1), TIMP metallopeptidase inhibitor 3, and also integrin α3 (ITGA3) genes 
upregulated by 36.74-, 35.86-, 35.62-, 33-, and 31.29-fold, respectively, as compared 
with the control groups in response to 50 µM resveratrol. In our study, the expression 
level of myc gene, an important oncogene in many cancer cells, was decreased 4-fold as 
compared with the control groups in response to 50 µM resveratrol. 
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Figure 3.11. Upregulated and downregulated genes in response to 10 µM resveratrol 
(threshold ˃ 4) 
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Figure 3.12. Upregulated and downregulated genes in response to 50 µM resveratrol 
(threshold ˃ 4) 
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CHAPTER 4 
 
CONCLUSION 
 
Chronic myeloid leukemia incidence is increasing day by day, unfortunately, 
and new therapeutic approaches are being investigated in order to cure this disease. 
Although current therapeutic approaches are effective to some extent, resistance cases 
are developing over time. Biologycally active sphingolipids are thought to be 
responsible for the maintenance of this resistance balance. Ceramide, the key molecule 
of sphingolipid family, leads to induction of apoptosis whereas S1P and 
glucosylceramide lead to induction of cell proliferation, and even emergence of 
resistance (Baran, et al. 2007, Gouaze-Andersson, et al. 2007). In case of a change in 
the balance of ceramide/S1P to the direction of S1P pole, cancer cells develop 
resistance resulting in cell survival. Manipulations of this ceramide/S1P balance by 
biochemical and/or molecular approaches to the direction of ceramide pole may open a 
new road in cancer therapy due to the cytotoxic and apoptotic effects of ceramide on 
cancer cells (Saddoughi, et al. 2008, French, et al. 2006).  
Ceramide-mediated apoptosis could be triggered by several different pathways. 
For instance, drugs used in clinic such as imatinib or docetaxel are known that they 
induce de novo ceramide generation, and also ceramide accumulation by inhibiting 
sphingomyelinases. Therefore, administration of these drugs results in the increase in 
intracellular ceramide levels. (Baran, et al. 2007). 
In addition to ceramide, resveratrol is also considered to sensitize cancer cells 
against chemotherapeutic agents in recent years. Resveratrol attracts highly attention 
because of its potentials such as anticancer, anti-inflammatory, apoptotic, 
chemosensitizer, etc. (Park, et al. 2009, Scarlatti, et al. 2007, Liao, et al. 2005). Several 
groups revealed cytotoxic effects of resveratrol on many cancer cells (Sahin, et al. 2007, 
Harikumar and Aggarwal 2008, Chakraborty, et al. 2008). In addition, chemosensitizer 
effects of resveratrol in sensitive and even resistant CML cells were reported (Puissant, 
et al. 2008). Moreover, radiosensitizer effects of resveratrol were reported in prostate, 
and non-small cell lung cancer cells (Scarlatti, et al. 2007, Liao, et al. 2005). There are 
also some studies that reveal the effects of resveratrol on ceramide generation (Scarlatti, 
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et al. 2007). In a study, Paola Signorelli et al have reported that resveratrol causes 
autophagy in gastric cancer cells via increasing intracellular ceramide levels (Signorelli, 
et al. 2009). In one another study, Ersilia Dolfini et al have showed that resveratrol may 
prevent the growth of MDA-MB-231 breast cancer cells through inducing de novo 
ceramide generation (Dolfini, et al. 2007). Moreover, Filippo Minutolo et al. have 
reported that resveratrol causes the endogenous ceramide accumulation in prostate and 
breast cancer cells (Minutolo, et al. 2005). Another research group from Germany 
reported that resveratrol enhances the ceramide synthesis in colorectal carcinoma cells 
(Ulrich, et al. 2007). However the roles of bioactive sphingolipids in resveratrol induced 
apoptosis and the effects of resveratrol on ceramide metabolizing genes have never been 
examined previously in chronic myeloid leukemia. In our study, we tried to show the 
effects of resveratrol on ceramide metabolism of K562 cells. Since we know 
C8:ceramide could pass easily through the cellular membrane, and also it has an 
appropriate fluidity in the cell membrane (Tokudomea, et al. 2009), we treated K562 
cells with C8:ceramide. 
In this study, we examined the mechanisms of resveratrol-induced apoptosis by 
focusing on ceramide metabolizing genes in K562 CML cells. We also investigated 
whether we could increase the sensitivity of K562 cells to resveratrol via increasing 
intracellular concentrations of ceramides by biochemical approaches. For this purpose, 
we treated K562 cells by increasing concentrations of resveratrol; C8:ceramide, an 
important cell-permeable analogue of natural ceramides; PDMP, the key inhibitor of 
GCS; and SK-1 inhibitor, and determined their cytotoxic effects by XTT cell 
proliferation assay. Our results showed a dose-dependent decreases in cell proliferation 
in response to reveratrol and in response to increased intracellular concentrations of 
ceramides. Apoptosis in K562 cells exposed to increasing concentrations of resveratrol, 
C8:ceramide, PDMP, and SK-1 inhibitor was also evaluated by examining the changes 
in caspase-3 enzyme activity and the loss of the mitochondrial membrane potential. The 
results revealed that resveratrol, C8:ceramide, PDMP, and SK-1 inhibitor induce 
apoptosis through increasing caspase-3 enzyme activity and inducing loss of 
mitochondrial membrane potential. Increasing intracellular concentrations of ceramides 
by C8:ceramide was suggested to be an effective approach to inhibit cancer cell growth 
(Saddoughi, et al. 2008). In order to determine possible synergistic effects of resveratrol 
and C8:ceramide or PDMP or SK-1 inhibitor, we assessed combinational treatments of 
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resveratrol with C8:ceramide, the inducer of de novo generation of apoptotic ceramides, 
PDMP, the inhibitor of GCS, and SK-1 inhibitor. When we applied the IC50 value of 
C8:ceramide (60 µM), and IC10 values of PDMP (20 µM), or SK-1 inhibitor (7 µM) 
with increasing concentrations of resveratrol (1- to 100 µM), synergistic 
antiproliferative effects on K562 cells were observed as compared to any agent alone 
and untreated controls. 10 µM resveratrol by itself could repress only 18% of cell 
proliferation while the same concentration of resveratrol together with C8:ceramide, 
PDMP, or SK-1 inhibitor inhibited 87-, 46-, and 42% of cell proliferation, respectively.  
The synergistic apoptotic effects of resveratrol in combination with 
C8:ceramide, PDMP, or SK-1 inhibitor were also observed by the changes in caspase-3 
enzyme activity and loss of mitochondrial membrane potential. As we increased the 
intracellular concentrations of ceramides by application of exogenous ceramide or by 
inhibition of the conversion of ceramides to glucosylceramide or sphingosine-1-
phosphate, the sensitivity of K562 cells to resveratrol increased synergistically. Our 
results were in agreement with the literature since Ogretmen et al clearly showed that 
both caspases and mitochondrial membrane potential are well-known downstream 
targets of ceramides (Ogretmen and Hannun 2004). 
Increases in intracellular concentrations of ceramides can be determined by 
expression levels of LASS gene family, GCS and SK-1 genes, and also by direct 
detection of ceramides by LC-MS. In this study, we examined the expression levels of 
ceramide-metabolizing genes by RT-PCR in an effort to determine the increases in 
intracellular ceramide concentrations. RT-PCR results of this study have shown for the 
first time that resveratrol treatment may be resulted in the upregulation of LASS2, 
LASS4, LASS5, and LASS6 genes in a dose-dependent manner in human chronic 
myeloid leukemia K562 cells. Furthermore, there were significant decreases in the 
expression levels of GCS and SK-1 genes in response to increasing concentrations of 
resveratrol in K562 cells. These results suggest that resveratrol increases intracellular 
concentrations of ceramides via both induction of its de novo synthesis, and also 
inhibition of the conversion of endogenous apoptotic ceramide to anti-apoptotic 
glucosylceramide and sphingosine-1-phosphate molecules. 
In addition, we also examined the expression levels of 84 genes related with 
apoptosis, cell cycle, angiogenesis, invasion and metastasis, etc. by human cancer 
pathway finder PCR array, in an effort to determine the effects of resveratrol on K562 
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cells. The results showed that in cancer cells, there is exactly like a war between the 
genes inhibitors of cell survival and the inducer ones. The fate of this war depends on 
the type of the genes upregulated. While we treated K562 cells with 50 µM resveratrol 
for 72 hours, expression levels of both some apoptotic genes and some cell survival 
genes were increased. However, the highest increase was determined in the expression 
level of maspin (SERPINB5) gene, which is a tumor suppressor. Tumor suppressive 
effects of maspin (MAmmary Serine Protease INhibitor) were reported in many cancer 
cells such as metastatic breast cancer cells (Zou, et al. 1994, Lele, et al. 2000), prostate 
cancer cells (Lockett, et al. 2006), and head and neck cancer cells (Marioni, et al. 2009). 
In cancer cells, maspin is generally inhibited via CpG methylation. However, some 
chemical agents, for example tamoxifen for breast cancer, and other demethylating 
agents increase maspin expression in cancer cells (Khalkhali-Ellis 2006). Maspin has 
been reported as an inhibitor of invasion, metastasis, and angiogenesis (Chen and Yates 
2006). PCR array results of our study have shown that expression level of maspin gene 
increases in response to elevated concentrations (10- and 50 µM) of resveratrol. The 
second gene among highly upregulated ones in response to 50 µM resveratrol was 
TNFRSF25, which is known as apoptosis-mediating receptor. This receptor interacts 
with an adapter molecule, known as TRADD. TNFRSF25 mediates activation of NFκB 
and induces apoptosis. 
However, the third highly upregulated gene in K562 cells in response to 50 µM 
resveratrol was FGFR2 in the results of the PCR array. Fibroblast growth factors 
(FGFs) are known as mitogenic signaling molecules playing roles in angiogenesis, 
wound healing, cell migration, and embryonic development. FGFRs are transmembrane 
catalytic receptors that have intracellular tyrosine kinase activity. Binding of FGF-
FGFR initiates FGFR dimerization. This dimerization allows the cytoplasmic kinase 
domains to transphosphorylate tyrosine residues and become activated. It is known that 
FGFR upregulation may lead to cell transformation and cancer. Moreover, the 
expression level of only one gene, myc oncogene, was decreased in response to 50 µM 
resveratrol. This downregulation of myc by resveratrol is consistent with the literature 
(Zhang, et al. 2006). 
In conclusion, our overall results showed that there were synergistic apoptotic 
effects of the combinations of resveratrol with C8:ceramide or PDMP or SK-1 inhibitor 
on K562 CML cells, and also these results confirmed the cytotoxic effects of resveratrol 
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on these cells. More importantly, we have shown for the first time that resveratrol 
triggers apoptosis through increasing expression levels of LASS genes and inhibiting 
the expression levels of GCS and SK-1 in human K562 CML cell lines. In addition, we 
also investigated for the first time that resveratrol upregulates the maspin expression, 
which leads to tumor suppression. Therefore, when we compare the PCR array results 
with the results of the apoptotic effects of resveratrol, we can suggest that resveratrol 
contributes some of the anti-survival genes and allows them to be victors of the war. 
Taking together, all these results may open the way of using resveratrol and ceramides 
as a novel therapeutic or supportive agents in CML therapy. 
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